Hemogenyx Pharmplc Ls 01 Stock Cash Per Share
| 5HU Stock | EUR 4.14 0.62 13.03% |
HEMOGENYX PHARMPLC LS 01 fundamentals help investors to digest information that contributes to HEMOGENYX PHARMPLC's financial success or failures. It also enables traders to predict the movement of HEMOGENYX Stock. The fundamental analysis module provides a way to measure HEMOGENYX PHARMPLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HEMOGENYX PHARMPLC stock.
HEMOGENYX |
HEMOGENYX PHARMPLC LS 01 Company Cash Per Share Analysis
HEMOGENYX PHARMPLC's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, HEMOGENYX PHARMPLC LS 01 has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The cash per share for all Germany stocks is 100.0% higher than that of the company.
HEMOGENYX Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HEMOGENYX PHARMPLC's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HEMOGENYX PHARMPLC could also be used in its relative valuation, which is a method of valuing HEMOGENYX PHARMPLC by comparing valuation metrics of similar companies.HEMOGENYX PHARMPLC is currently under evaluation in cash per share category among its peers.
HEMOGENYX Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Shares Outstanding | 979.75 M | |||
| Shares Owned By Insiders | 15.17 % | |||
| EBITDA | (2.62 M) | |||
| Net Income | (2.08 M) | |||
| Cash And Equivalents | 1.81 M | |||
| Total Debt | 1.63 M | |||
| Debt To Equity | 1.86 % | |||
| Current Ratio | 1.08 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.8 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 10 | |||
| Beta | 3.34 | |||
| Market Capitalization | 24.89 M | |||
| Z Score | 9.0 |
About HEMOGENYX PHARMPLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HEMOGENYX PHARMPLC LS 01's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HEMOGENYX PHARMPLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HEMOGENYX PHARMPLC LS 01 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HEMOGENYX Stock
HEMOGENYX PHARMPLC financial ratios help investors to determine whether HEMOGENYX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HEMOGENYX with respect to the benefits of owning HEMOGENYX PHARMPLC security.